BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peris K. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol 2021;184:133-40. [PMID: 32119111 DOI: 10.1111/bjd.18983] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Özkur E, Karadağ AS, Üstüner P, Aksoy B, Eşme P, Çalışkan E, Akoğlu G, Kalkan G, Demirseren DD, Polat M, Ozden MG, Kılınç F, Yalçınkaya İyidal A, Kıvanç Altunay İ, Türkmen M, Uğurer E, Baysak S, Fettahlıoğlu Karaman B, Mammadlı K, Baykal Selçuk L, Türkoğlu Z, Atcı T, Didar Balcı D, Adışen E, Temel B, Aktan Ş, Kaçar N, Gündüz K, Türel Ermertcan A, Özdemir M, Ünal Çakıter A, Çölgeçen E, Uçmak D, Kelekçi H, Ataseven A, Durmaz K, Kaya Özden H, Engin B, Yazıcı S, Alpsoy E. Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. Clin Exp Dermatol 2021;46:532-40. [PMID: 33030217 DOI: 10.1111/ced.14478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Molinelli E, Diotallevi F, Simonetti O, Brisigotti V, Sapigni C, Radi G, Campanati A, Offidani A. Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy. Dermatol Ther 2020;33:e14256. [PMID: 32860474 DOI: 10.1111/dth.14256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Molinelli E, Sapigni C, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opin Drug Metab Toxicol 2020;16:1019-37. [PMID: 32896186 DOI: 10.1080/17425255.2020.1810233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Odorici G, Pacetti L, Forconi R, Schettini N, Zedde P, Corazza M, Bettoli V. Seven Years-Experience of adalimumab therapy for hidradenitis suppurativa in a real-life dermatologic setting. J Dermatolog Treat 2021;:1-10. [PMID: 33843413 DOI: 10.1080/09546634.2021.1914309] [Reference Citation Analysis]
5 Montero-Vilchez T, Salvador-Rodriguez L, Sanchez-Diaz M, Cuenca-Barrales C, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice. Dermatol Ther 2020;33:e14254. [PMID: 32860480 DOI: 10.1111/dth.14254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
7 Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, Zemskov SV, Abeni D, Tzellos T, Szepietowski JC, Zouboulis CC. Quality of Life in Hidradenitis Suppurativa: An Update. Int J Environ Res Public Health 2021;18:6131. [PMID: 34204126 DOI: 10.3390/ijerph18116131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Marzano AV, Moltrasio C, Genovese G, Muratori S, Dapavo P, Fabbrocini G, Patrizi A, Sechi A, Micali G, Pellegrino M, Gisondi P, Dini V, Bianchi L, Fania L, Offidani A, Prignano F, Atzori L, Miraglia E, Cannavò SP, Bettoli V, Stingeni L, Balestri R, Venturini M, Peris K. Hidradenitis suppurativa and adalimumab in the COVID-19 era. Eur J Dermatol 2020;30:748-9. [PMID: 33337329 DOI: 10.1684/ejd.2020.3927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nazzaro G, Calzari P, Passoni E, Vaienti S, Moltrasio C, Barbareschi M, Muratori S, Veraldi S, Marzano AV. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients. Dermatol Ther 2021;34:e14706. [PMID: 33368976 DOI: 10.1111/dth.14706] [Reference Citation Analysis]
10 Aarts P, Dudink K, Vossen ARJV, van Straalen KR, Ardon CB, Prens EP, van der Zee HH. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. Drugs 2021;81:1397-410. [PMID: 34283386 DOI: 10.1007/s40265-021-01566-2] [Reference Citation Analysis]
11 Johnston DGW, Kirby B, Tobin DJ. Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction? Exp Dermatol 2021;30:1554-68. [PMID: 34418166 DOI: 10.1111/exd.14451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol 2021. [PMID: 34378812 DOI: 10.1111/jdv.17598] [Reference Citation Analysis]
13 Wollina U, Brzezinski P, Koch A, Philipp-Dormston WG. Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa-A narrative review. Dermatol Ther 2020;33:e13877. [PMID: 32558202 DOI: 10.1111/dth.13877] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Shah M, Sachdeva M, Alavi A. Work impairment in a woman with severe hidradenitis suppurativa after delayed diagnosis: A call for action. Int J Womens Dermatol 2020;6:327-8. [PMID: 33015296 DOI: 10.1016/j.ijwd.2020.05.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]